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ABSTRACT
The choice of management for patients with adnexal tumors requires careful pre-surgical assessment. In case of adnexal 
masses, the diagnostic difficulties arise from the heterogenic nature of the adnexal diseases, presence of multiple functional 
changes, and lack of early symptoms of malignancy. A reliable pre-surgical differentiation cannot be performed using clinical 
features, ultrasound examination, or tumor markers alone. New diagnostic techniques and novel markers are under inves-
tigations, however no single test can be used to conclusively differentiate between malignant and non-malignant adnexal 
masses. Mathematical models and scoring systems based on different clinical, ultrasonographic and laboratory parameters 
alone or together may facilitate the diagnosis. Selected mathematical models and scoring systems are presented in this 
article. Models using only ultrasound features include simple rules, regression models, Gynecologic Imaging Report and 
Data System, and various morphologic scores. Some logistic regression models are based on multiple clinical and ultrasound 
data. The OVA1 test is based on five tumor markers without using other data. The Risk of Malignancy Algorithm uses two 
tumor markers with one clinical parameter. i.e. the menopausal status. Some models used clinical, ultrasound and tumor 
marker data together. This group of models includes risk of malignancy indices, artificial neural networks, and the ADNEX 
model. Although some of these models have been compared in the literature, more prospective studies are needed to 
select the most effective model, to develop the existing models, or to create new more effective models of oncological 
assessment of the adnexal tumors.
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INTRODUCTION
Until today, no single imaging or laboratory test could 
be the source of a reliable differentiation between malignant 
and non-malignant adnexal tumors. The initial diagnosis 
of the adnexal masses depends on clinical examination, 
ultrasound assessment, and tumor marker levels. Subjective 
ultrasound assessment of the adnexal tumors is one of the 
basic methods used for their classification. However, result 
interpretation depends mainly on the experience of the 
examiner [1, 2]. Thus, there exists a distinct need to establish 
certain criteria and definitions for ultrasound evaluation of 
the adnexa and their pathologies. In 2000, the International 
Ovarian Tumor Analysis (IOTA) group presented uniform 
terms and definitions for ultrasound description of the ad-
nexal masses. The IOTA methodology enables ultrasound 
examiners to assess adnexal pathologies in the same way, 
independently of their experience [3]. Logistic regression 
models are systemic mathematical methods to establish 
an algorithm for detecting the likelihood of an occurrence 
of a certain event. They are already used in the management 
of adnexal masses to detect malignancy, using multiple 
different parameters to improve pre-surgical diagnostic 
differentiation of these pathologies. The final histological 
diagnosis of the adnexal tumors correlates with numerous 
parameters rather than with a single one. Forward stepwise 
selection of the parameters during model formation enables 
incorporation of the most important parameters into the 
equation of the logistic model. The result of these mod-
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els represents the likelihood of malignancy and can help 
choose the optimal method of adnexal tumor management, 
whether expectant or operative [4]. Precise pre-operative 
assessment is of great importance for patients in the re-
productive age as in this case the surgical approach should 
consider fertility-sparing surgery for malignant diseases and 
minimal invasive surgery for non-malignant pathologies 
to preserve the ovarian reserve [5]. The choice of radical 
surgery is essential for patients with adnexal malignan-
cies. Nowadays, laparoscopy can replace laparotomy in the 
treatment and staging of ovarian cancer [6]. In this group 
of patients, aseptic oncologic methods should be used to 
prevent iatrogenic rupture of adnexal malignant masses and 
dissemination of malignant cells [7]. Pre-surgical suspicion 
of malignant diseases enables examiners to refer patients to 
gynecologic oncology units without delay. The overall sur-
vival rate of patients treated in these units is higher than in 
non-oncologic units [8]. In this review article, we present 
selected mathematical models and scoring systems used for 
pre-surgical differentiation of adnexal tumors. Some of the 
parameters used in certain models e.g. papillary projection, 
are not compatible with the IOTA group definitions since 
these models had been introduced earlier. This may cause 
confusion as papillary projection cannot have the height 
of < 3 mm according to the IOTA group [3].
ULTRASOUND PARAMETER-BASED MODELS
Simple rules
In 2008, the IOTA group presented the simple rules 
method to classify adnexal masses pre-operatively. Ac-
cording to these rules, there are five malignant ultrasound 
features (M — malignant) and five benign features (B — be-
nign). Malignant ultrasound features include irregular solid 
tumor, ascites, at least four papillary projections, irregular 
multilocular-solid mass with a diameter of ≥ 100 mm, in-
tense vascularization of the mass assessed as grade 4 on 
the scale from 1 to 4 according to the IOTA terms and defi-
nitions. The following ultrasound features are considered 
as benign: unilocular cyst, solid areas with the maximum 
diameter of < 7 mm, acoustic shadows, regular multilocu-
lar cyst with the maximum diameter of < 100 mm, and 
absence of blood flow in color Doppler scan, i.e. grade 1 
according to IOTA. The presence of at least one (M) ma-
lignant feature, in the absence of (B) benign features, will 
classify the mass as malignant. The presence of at least 
one (B) benign feature, with the absence of any (M) ma-
lignant features, enable the examiner to classify the mass 
as benign. In case of the presence of both, benign and 
malignant features, or when none of the them can be 
confirmed, the mass will be assessed as ‘inconclusive’ and 
will require further assessment by an expert. The sensitiv-
ity and specificity of simple rules to detect malignancy in 
the study of the IOTA group were 95% and 91%, respec-
tively. Simple rules can be used by non-expert examiners 
to classify adnexal masses. However, approximately 25% 
of them will be considered as inconclusive and will need 
assessment by an ultrasound expert [2].
Regression models
In the study of Prompeler HJ et al., from 1997, an ul-
trasound-based regression model was presented. The fol-
lowing ultrasound parameters were included: ascites, solid 
areas without acoustic shadows, masses with at least 30% 
solid area, tumor diameter, multilocular structures, and 
surface of the cyst. At cut-off level of 10%, the sensitiv-
ity and specificity were 86.5% and 92.6%, respectively for 
premenopausal and 93% and 82.7%, respectively for post-
menopausal patients [9].
Gynecologic Imaging — Report and Data System
In 2009, Amor F et al., presented an ultrasound-based 
Gynecologic Imaging — Report and Data System (GI-RADS), 
which has five grades of ultrasonographic assessment of 
the adnexa and their pathologies [10]. The system is based 
on the concept of Breast Imaging Report and Data Sys-
tem (BI-RADS). BI-RADS classification, used primarily for 
mammography assessment, is now used for the ultrasound 
evaluation of the breast. This classification system helps to 
communicate between sonographers and clinicians in the 
management of breast pathologies [11]. According to this 
system, normal ultrasound appearance of an ovary with no 
risk of malignancy is considered to be grade 1. The presence 
of functional changes, most probably benign, with malig-
nancy probability of < 1%, represents grade 2. These chang-
es include follicular cysts, corpora lutea, and hemorrhagic 
cysts. Grade 3 represents adnexal masses, probably benign, 
with the malignancy probability of 1–4%. The following 
pathologies belong to this grade: endometriotic cysts, sim-
ple cysts, mature teratoma, hydrosalpinx, paraductal cysts, 
peritoneal pseudocysts, pedunculated fibroids, and inflam-
matory masses. Adnexal tumors, probably malignant, with 
the malignancy probability of 5–20% constitute grade 4. 
This grade includes tumors which cannot be considered as 
grades 1–3, having one or two of the following malignant 
ultrasound features: papillary projections, septa, solid ar-
eas, ascites and vascularization within solid areas, papillary 
projections and central part of the solid tumors assessed in 
color or power Doppler examination. Adnexal masses, most 
probably malignant, which have at least three malignant 
features represent grade 5. The risk of malignancy in this 
grade exceeds 20% [10, 11]. This system may help physicians 
to choose the most appropriate, grade-dependent method 
of management. Expectant management is the method of 
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choice for grade 2 tumors. Grade 3 adnexal masses need 
surgical intervention by gynecologists, while grade 4–5 pa-
tients should be referred to gynecological oncologist for 
further management [11]. The sensitivity and specificity 
of GI-RADS in the study of Amor et al., were 92% and 97%, 
respectively [10]. 
Morphologic scores
Morphologic ultrasound features are used in these mod-
els. A certain value can be allocated for each ultrasound 
feature. The values of the parameters are summated and the 
sum represents the result of the morphologic model which 
can classify the adnexal mass as malignant or non-malignant 
at certain cut-off level [12–15]. Examples of morphological 
scores for the assessment of adnexal masses are shown in 
Table 1.
CLINICAL DATA AND ULTRASOUND 
PARAMETER-BASED MODELS
Logistic regression models
The model, proposed by Tailor et al., in 1997, included 
three parameters in the equation: age, time averaged maxi-
mum velocity (TAMXV), and presence or absence of papillary 
projections (values of 1 and 0, respectively). The following 
equation is used: „probability of malignancy = 1/1 + e-z”, 
where z = (0.1273x age) + (0.2794x TAMXV) + (4.4136x pap-
illary projection score) – 14.2046, and e is the mathemati-
cal constant and the base value of the natural logarithm. 
A cut-off level at 50% was established for this model. The 
sensitivity and specificity in that study were 86.7% and 
98.1%, respectively [4].
The IOTA group suggested two logistic regression mod-
els in 2005. A total of 12 clinical and ultrasound parameters 
were used in the logistic regression model 1 (LR1). These 
parameters with the value allocated for each parameter in 
the final equation are presented in Table 2 [16].
The sensitivity and specificity of this model at 
cut-off level 10% reached 93% and 77%, respectively. 
The probability of malignancy is calculated in the fol-
lowing equation: y = 1/(1 + e−z), where z = −6.7468 
+ 1.5985 (1) – 0.9983 (2) + 0.0326 (3) + 0.00841 (4) – 0.8577 (5) 
+ 1.5513 (6) + 1.1737 (7) + 0.9281 (8) + 0.0496 (9) + 1.1421 (10) 
– 2.3550 (11) + 0.4916 (12) and e is the mathematical constant 
and base value of natural logarithms. This model is the result 
of multi-center prospective studies [16].
The IOTA group modified the first logistic regression 
model and introduced the logistic regression model 2 (LR2), 
which is based only on 6 parameters. Clinical data included 
only (1) patient age. Ultrasound parameters included (2) 
ascites, (3) papillary projections with detectable blood flow, 
(4) maximum diameter of the largest solid area, (5) irregular 
cyst wall, and (6) acoustic shadows. Interpretation of these 
parameters with the values used for them in the equation is 
identical to Table 2. For this simplified model, the following 
equation is used: y = 1/(1 + e−z), where z = −5.3718 + 0.0354 (1) 
+ 1.6159 (2) + 1.1768 (3) + 0.0697 (4) + 0.9586 (5) − 2.9486 (6), 
e is the mathematical constant and base value of natural 
logarithms. At cut-off level of 10%, the sensitivity and speci-
ficity of this model reached 92% and 75%, respectively [16].
Serum tumor marker-based models
A laboratory test, commercially known as OVA1, was 
cleared by the Food and Drug Administration (FDA) in 
2009 [17]. This test uses an algorithm based on five tumor 
markers to predict adnexal malignancy. The following mark-
ers are used in this model: CA125, transferrin, transthyretin 
(prealbumin), apolipoprotein A1 and β2-microglobulin. The 
result of this test is calculated using the Ovacal program, 
which includes an algorithm for pre-surgical prediction of 
the presence of malignant ovarian disease. The result of the 
test has a range of 0–10. High probability of malignancy 
is defined as a result ≥ 5 for premenopausal and 4.4 for 
postmenopausal patients. The use of multiple tumor mark-
ers in this model increases the diagnostic performance of 
CA125 alone. The sensitivity and specificity of OVA1 test in 
the study of Ueland FR et al., in 2011 reached 93% and 43%, 
respectively [18].
Clinical data and tumor marker-based models
In 2009, Moore RG et al., presented the Risk of Ma-
lignancy Algorithm (ROMA) for the assessment of risk of 
malignancy of adnexal tumors. This algorithm is based 
on serum level of CA125 and Human Epididymis protein 
(HE4), taking into consideration the menopausal status of 
the patient. Predictive index (PI) for premenopausal pa-
tients is calculated in the following way: PI = –12.0 + 2.38* 
LN(HE4) + 0.0626*LN(CA125), while for postmenopausal 
patients: PI = – 8.09 + 1.04*LN(HE4) + 0.732*LN(CA125), 
where LN is the natural logarithm. Predictive probability (PP) 
is calculated in the following way: PP = exp(PI)/[1-exp(PI)]. 
Cut-off levels used to define high risk of ovarian malignancy 
by Moore et al., are 13.1% and 27.7% for pre- and post-
menopausal patients, respectively. Sensitivity and specific-
ity of ROMA for premenopausal patients were 76.5% and 
74.8%, respectively, while for postmenopausal patients: 
92.3% and 74.7%, respectively. In their study, menopause 
was defined as amenorrhea for at least one year, history of 
bilateral ovariectomy, or age > 55 years for patients who did 
not remember the date of the last menstrual period. The 
use of tumor markers without considering ultrasound pa-
rameters eliminated the problem of subjective assessment 
of ultrasound examiners and the need to consult experts 
during the assessment process [19]. 
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CLINICAL DATA, ULTRASOUND PARAMETERS 
AND TUMOR MARKER LEVEL-BASED MODELS
Risk of malignancy indices 
A multimodal system based on ultrasound score (U), 
menopausal status (M), and tumor marker CA125 was con-
structed by Jacobs et al. in 1990. The following ultrasound 
parameters are used during the ultrasound examination: 
presence of multilocular cyst, solid tumors, ascites, bilateral le-
sions, and metastases. For each ultrasound parameter a value 
of 1 was allocated. Ultrasound score (U) equals 0 when there 
are no confirmed ultrasound features, U = 1 when there is 
only one ultrasound feature, and U = 3 when there are 2 to 
5 features. Menopausal score (M) is 1 for premenopausal pa-
tients and 3 for postmenopausal patients. Risk of Malignancy 
Index (RMI I) is calculated according to the following formula: 
RMI I = U × M × CA125. Serum level of CA125 (U/mL) is used 
directly in the formula. When the cut-off level of RMI I was 
set at 200, the sensitivity and specificity in differentiating 
between malignant and non-malignant masses in this study 
were 85% and 97%, respectively [20].
In 1996, Tinglustad S et al., modified RMI I and presented 
RMI II. These authors used the same formula, modifying 
only the values used for the U and M scores. The U score has 
a value of 1, if there are no ultrasound features or when there 
is only one ultrasound feature. At least two features will give 
a value of U = 4. An M value of 1 was given for premeno-
pausal and 4 for postmenopausal patients. In that study, 
the same cut-off level, i.e. 200, was used, resulting in the 
sensitivity and specificity of 80% and 92%, respectively [21].
In 1999, Tinglustad S et al., yet again modified the for-
mula and presented RMI III. The U score has a value of 1 when 
there is only one ultrasound feature and a value of 3 when 
there are at least two confirmed features. The M score had 
values identical to RMI I. The same cut-off level was used, 
with the sensitivity and specificity for differentiating be-
tween malignant adnexal tumors reaching 71% and 92%, 
respectively [22].
In 2009, RMI was modified by Yamamato Y et al., who 
presented RMI IV. A new element in the form of the maxi-
mum diameter (S) of the mass was used in this modification. 
The U and M scores had values identical to those used in 
RMI II. The S parameter had a value of 1 when the maximum 
diameter of the mass was < 70 mm, and S = 2 when the 
maximum diameter was ≥ 70 mm. RMI IV was calculated 
using the formula: RMI IV = U × M × CA125 × S. Using this 
method at cut-off level of 450, the sensitivity and specificity 
were 86.8% and 91%, respectively [23].
Artificial neural networks (ANN)
Artificial neural networks (ANN) can be described as 
systems which change information, in the form of numeri-
cal values, through the synapses. This analytic model was 
presented by Timmerman D et al. in 1999. The following 
parameters were used in the first variant of ANN (ANN1): 
papillary projections, blood flow, CA125 level and the meno-
pausal status, while in the second version (ANN2) the fol-
lowing parameters were considered: papillary projections, 
smooth surface, unilocular cyst, ascites, bilateral lesions, 
tumor marker CA125 and the menopausal status. The prob-
ability of malignancy is calculated using sophisticated math-
ematical models structured by the authors of that study. In 
ANN1, the probability of malignancy > 45% revealed the 
sensitivity and specificity of 87.5% and 92.7%, respectively, 
while in ANN2 the probability of > 60% resulted in the sen-
sitivity and specificity of 93.8% and 95.1%, respectively [24].
Table 2. Parameters used in the logistic regression model 1 proposed 
by the IOTA group with the interpretation of the data and values 
used in the formula
Examined parameter
Interpretation 
of the 
parameters
Value allocated 
for the interpreted 
parameters in the 
final formula
(1) Personal history of 
ovarian cancer
Yes 1
No 0
(2) Current use of 
hormonal therapy
Yes 1
No 0
(3) Age – Age in years
(4) Maximum diameter of 
the tumor –
Maximum diameter 
of the tumor in mm
(5) Pain during ultrasound 
examination
Yes 1
No 0
(6) Presence of ascites
Yes 1
No 0
(7) Presence of papillary 
projections with 
detectable blood flow
Yes 1
No 0
(8) Solid tumor
Yes 1
No 0
(9) Maximum diameter of 
the largest solid area –
Maximum diameter 
of the largest solid 
area in mm, not 
more than 50 mm
(10) Irregular cyst wall
Yes 1
No 0
(11) Presence of acoustic 
shadows
Yes 1
No 0
(12) Vascularization score 
according to the IOTA 
group
Absent 1
Mild 2
Moderate 3
Severe 4
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Prediction model
In 2014, the IOTA group presented the Assessment of 
Different NEoplasias in the adneXa (ADNEX). This method 
can predict the probability of malignancy in five main cat-
egories (benign, borderline, stage I malignant disease, stage 
II–IV malignant disease and metastases). This model is based 
on serum CA125 levels, two clinical parameters and six ul-
trasound parameters. Clinical data include patient age and 
type of medical facility where the ultrasound was performed 
(oncological or not). Ultrasound features include maximum 
diameter of the lesion, maximum diameter of the largest solid 
area, presence of multilocular cyst with more than 10 locules, 
number of papillary projections, acoustic shadows and asci-
tes. For cut-off level of 10%, the sensitivity and specificity were 
96.5% and 71.3%, respectively. Precise prediction of adnexal 
tumor type helps to choose the most appropriate method of 
management. In this model, CA125 level may be omitted if 
not available, however this can bias the result, since CA125 is 
one of the most important predicting factors in the model. 
The ADNEX model, simple rules and the logistic regression 
models of the IOTA group are available at www.iotagroup.
org and as mobile applications [25].
SUMMARY
In this article, we presented mathematical models and 
scoring systems which are used to calculate the probability 
of malignancy in patients with adnexal tumors [26]. Despite 
a great number of models which are proposed by different 
medical centers, until today there exists no single model 
or system which can conclusively discriminate between 
malignant and non-malignant adnexal tumors. Introduction 
of uniform definitions by the IOTA group enables examin-
ers anywhere in the world to perform the examination in 
a systemic way, independently of the experience of the 
examiners. Also, a uniform ultrasound description of the 
adnexal tumors allows for result comparison between dif-
ferent centers in the world. 
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